Indication
Familial Partial Lipodystrophy
3 clinical trials
5 products
Clinical trial
A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients With Familial Partial LipodystrophyStatus: Terminated, Estimated PCD: 2023-10-31
Product
REGN4461Product
Matching PlaceboClinical trial
Phase 2 Study of Obeticholic Acid for Lipodystrophy PatientsStatus: Completed, Estimated PCD: 2022-10-01
Product
Obeticholic acidProduct
PlaceboClinical trial
Expanded-Access for the Use of Metreleptin in Patients With Partial Lipodystrophy Associated With Diabetes Mellitus or HypertriglyceridemiaStatus:
Product
Metreleptin